Published

Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Expert opinion on emerging drugs
Date: 2024-09-01
Source: PubMed
DOI: 10.1080/14728214.2024.2342951
PubMed: 38606899

Authors

Köhne S Hillemacher T Glahn A Bach P

Watch author

Derived topics and classifications

psilocybin Addiction Clinical Trial Review Article Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.2024-09-01

Related papers

Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010-2025): 15 Years of Progress (or Lack Thereof).CNS drugs · 2026-02-01 Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use DisordersCanadian Agency for Drugs and Technologies in Health, Ottawa (ON) · 2021-06-01 The Return of Psychedelics: Still Time to Prevent TragedyPsychiatric News · 2021-03-31 Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.Journal of psychoactive drugs · 2017-01-01 Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.Drugs · 2026-08-01 Classic psychedelics may treat depressive disorders, but more evidence and legislative changes are requiredDrugs & Therapy Perspectives · 2025-11-04 A Scoping Review of Research in Naturalistic Studies with Psychedelics.Journal of psychoactive drugs · 2025-06-28 Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.Journal of psychoactive drugs · 2024-01-01